Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant	Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease	Recruiting	Phase 2	2026-06-04		NCT05424003

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novo Nordisk A/S	181
University of Virginia	201

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Virginia Commonwealth University	Richmond	United States	156

Clinical trials